Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Julphar
US Department of Justice
Queensland Health
Merck
Colorcon

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,572,920

« Back to Dashboard

Summary for Patent: 7,572,920
Title:Benzimidazole derivative and use as a II receptor antagonist
Abstract:The present invention relates to a compound represented by the formula (I) ##STR00001## wherein R.sup.1 is a group represented by the formula ##STR00002## wherein R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently a hydrogen atom or a C.sub.1-6 alkyl, or a salt thereof. The compound of the present invention is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and metabolic diseases such as diabetes and the like.
Inventor(s): Kuroita; Takanobu (Katano, JP), Sakamoto; Hiroki (Amagasaki, JP), Ojima; Mami (Amagasaki, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:11/466,633
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,572,920
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,572,920

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-001 Feb 25, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERTENSION ➤ Sign Up
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERTENSION ➤ Sign Up
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERTENSION ➤ Sign Up
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-002 Dec 20, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERTENSION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,572,920

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2004-048928Feb 25, 2004

International Family Members for US Patent 7,572,920

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 047972 ➤ Sign Up
Argentina 094588 ➤ Sign Up
Austria 370136 ➤ Sign Up
Austria 440095 ➤ Sign Up
Australia 2005214271 ➤ Sign Up
Brazil PI0507984 ➤ Sign Up
Canada 2557538 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Baxter
Federal Trade Commission
Cantor Fitzgerald
Citi
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.